Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Alzheimer's Disease

Free Subscription Articles published in Nat Med Retrieve available abstracts of 59 articles: HTML format

Single Articles

September 2025
1. TIDEMAN P, Karlsson L, Strandberg O, Calling S, et al
   Primary care detection of Alzheimer's disease using a self-administered digital cognitive test and blood biomarkers.
   Nat Med. 2025 Sep 15. doi: 10.1038/s41591-025-03965.
   PubMed     Abstract available
   
   
   
2. ALI M, Erabadda B, Chen Y, Xu Y, et al
   Author Correction: Shared and disease-specific pathways in frontotemporal dementia and Alzheimer's and Parkinson's diseases.
   Nat Med. 2025 Sep 2. doi: 10.1038/s41591-025-03970.
   PubMed    
   
   
   August 2025
3. SHVETCOV A, Johnson ECB, Winchester LM, Walker KA, et al
   APOE epsilon4 carriers share immune-related proteomic changes across neurodegenerative diseases.
   Nat Med. 2025;31:2590-2601.
   PubMed     Abstract available
   
   
   
4. IMAM F, Saloner R, Vogel JW, Krish V, et al
   The Global Neurodegeneration Proteomics Consortium: biomarker and drug target discovery for common neurodegenerative diseases and aging.
   Nat Med. 2025;31:2556-2566.
   PubMed     Abstract available
   
   
   
5. OH HS, Le Guen Y, Rappoport N, Urey DY, et al
   Plasma proteomics links brain and immune system aging with healthspan and longevity.
   Nat Med. 2025;31:2703-2711.
   PubMed     Abstract available
   
   
   July 2025
6. CHUI DH, Tanahashi H, Ozawa K, Ikeda S, et al
   Editorial Expression of Concern: Transgenic mice with Alzheimer presenilin 1 mutations show accelerated neurodegeneration without amyloid plaque formation.
   Nat Med. 2025 Jul 25. doi: 10.1038/s41591-025-03903.
   PubMed    
   
   
   
7. ALI M, Erabadda B, Chen Y, Xu Y, et al
   Shared and disease-specific pathways in frontotemporal dementia and Alzheimer's and Parkinson's diseases.
   Nat Med. 2025 Jul 15. doi: 10.1038/s41591-025-03833.
   PubMed     Abstract available
   
   
   
8. GATES B
   Global collaboration is key to decoding Alzheimer's disease.
   Nat Med. 2025 Jul 15. doi: 10.1038/d41591-022-00044.
   PubMed    
   
   
   
9. COLONNA M, Holtzman DM
   Rethinking TREM2 as a target for Alzheimer's disease after the INVOKE-2 trial failure.
   Nat Med. 2025 Jul 2. doi: 10.1038/s41591-025-03816.
   PubMed    
   
   
   June 2025
10. SELKOE DJ
    In Alzheimer's disease, dimers do the damage.
    Nat Med. 2025;31:1727.
    PubMed    
    
    
    April 2025
11. 
    Cerebrospinal fluid biomarker predicts dementia onset and progression in Alzheimer's disease.
    Nat Med. 2025 Apr 28. doi: 10.1038/s41591-025-03700.
    PubMed    
    
    
    
12. 
    Microglia drive amyloid-beta clearance in immunized patients with Alzheimer's disease.
    Nat Med. 2025 Apr 22. doi: 10.1038/s41591-025-03677.
    PubMed    
    
    
    
13. O'LEARY K
    Anti-amyloid could help prevent genetic form of Alzheimer's disease.
    Nat Med. 2025 Apr 17. doi: 10.1038/d41591-025-00026.
    PubMed    
    
    
    
14. PALMQVIST S, Warmenhoven N, Anastasi F, Pilotto A, et al
    Plasma phospho-tau217 for Alzheimer's disease diagnosis in primary and secondary care using a fully automated platform.
    Nat Med. 2025 Apr 9. doi: 10.1038/s41591-025-03622.
    PubMed     Abstract available
    
    
    
15. ANDRIEU S, Bateman RJ, Bereczki E, Bose N, et al
    Harnessing artificial intelligence to transform Alzheimer's disease research.
    Nat Med. 2025 Apr 1. doi: 10.1038/s41591-025-03632.
    PubMed    
    
    
    March 2025
16. HORIE K, Salvado G, Koppisetti RK, Janelidze S, et al
    Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer's disease.
    Nat Med. 2025 Mar 31. doi: 10.1038/s41591-025-03617.
    PubMed     Abstract available
    
    
    
17. OH HS, Urey DY, Karlsson L, Zhu Z, et al
    A cerebrospinal fluid synaptic protein biomarker for prediction of cognitive resilience versus decline in Alzheimer's disease.
    Nat Med. 2025 Mar 31. doi: 10.1038/s41591-025-03565.
    PubMed     Abstract available
    
    
    
18. VAN OLST L, Simonton B, Edwards AJ, Forsyth AV, et al
    Author Correction: Microglial mechanisms drive amyloid-beta clearance in immunized patients with Alzheimer's disease.
    Nat Med. 2025 Mar 28. doi: 10.1038/s41591-025-03664.
    PubMed    
    
    
    
19. GRANDE G, Valletta M, Rizzuto D, Xia X, et al
    Blood-based biomarkers of Alzheimer's disease and incident dementia in the community.
    Nat Med. 2025 Mar 26. doi: 10.1038/s41591-025-03605.
    PubMed     Abstract available
    
    
    
20. RAJJI TK, Baksh SN, Shade DM, Ismail Z, et al
    Escitalopram for agitation in Alzheimer's dementia: a randomized controlled phase 3 trial.
    Nat Med. 2025 Mar 25. doi: 10.1038/s41591-025-03569.
    PubMed     Abstract available
    
    
    
21. RASH BG, Ramdas KN, Agafonova N, Naioti E, et al
    Allogeneic mesenchymal stem cell therapy with laromestrocel in mild Alzheimer's disease: a randomized controlled phase 2a trial.
    Nat Med. 2025 Mar 10. doi: 10.1038/s41591-025-03559.
    PubMed     Abstract available
    
    
    
22. VAN OLST L, Simonton B, Edwards AJ, Forsyth AV, et al
    Microglial mechanisms drive amyloid-beta clearance in immunized patients with Alzheimer's disease.
    Nat Med. 2025 Mar 6. doi: 10.1038/s41591-025-03574.
    PubMed     Abstract available
    
    
    
23. MOUTINHO S
    Women twice as likely to develop Alzheimer's disease as men - but scientists do not know why.
    Nat Med. 2025;31:704-707.
    PubMed    
    
    
    
24. DUFF EP, Zetterberg H, Heslegrave A, Dehghan A, et al
    Plasma proteomic evidence for increased beta-amyloid pathology after SARS-CoV-2 infection.
    Nat Med. 2025;31:797-806.
    PubMed     Abstract available
    
    
    February 2025
25. ISLAM T, Hill E, Abrahamson EE, Servaes S, et al
    Phospho-tau serine-262 and serine-356 as biomarkers of pre-tangle soluble tau assemblies in Alzheimer's disease.
    Nat Med. 2025 Feb 10. doi: 10.1038/s41591-024-03400.
    PubMed     Abstract available
    
    
    
26. LLIBRE-GUERRA JJ, Fernandez MV, Joseph-Mathurin N, Bian S, et al
    Longitudinal analysis of a dominantly inherited Alzheimer disease mutation carrier protected from dementia.
    Nat Med. 2025 Feb 10. doi: 10.1038/s41591-025-03494.
    PubMed     Abstract available
    
    
    December 2024
27. MOGUILNER S, Baez S, Hernandez H, Migeot J, et al
    Brain clocks capture diversity and disparities in aging and dementia across geographically diverse populations.
    Nat Med. 2024;30:3646-3657.
    PubMed     Abstract available
    
    
    July 2024
28. FORTEA J, Vaque-Alcazar L, Pegueroles J, Alcolea D, et al
    Reply to: Challenges to identifying risk versus protective factors in Alzheimer's disease.
    Nat Med. 2024 Jul 18. doi: 10.1038/s41591-024-03159.
    PubMed    
    
    
    
29. PAPPALETTERA C, Carrarini C, Cappa S, Caraglia N, et al
    Challenges to identifying risk versus protective factors in Alzheimer's disease.
    Nat Med. 2024 Jul 18. doi: 10.1038/s41591-024-03158.
    PubMed    
    
    
    
30. ROSENZWEIG N, Kleemann KL, Rust T, Carpenter M, et al
    Sex-dependent APOE4 neutrophil-microglia interactions drive cognitive impairment in Alzheimer's disease.
    Nat Med. 2024 Jul 3. doi: 10.1038/s41591-024-03122.
    PubMed     Abstract available
    
    
    June 2024
31. JACK CR JR, Andrews SJ, Beach TG, Buracchio T, et al
    Revised criteria for the diagnosis and staging of Alzheimer's disease.
    Nat Med. 2024 Jun 28. doi: 10.1038/s41591-024-02988.
    PubMed    
    
    
    
32. FORTEA J, Pegueroles J, Alcolea D, Belbin O, et al
    Publisher Correction: APOE4 homozygosity represents a distinct genetic form of Alzheimer's disease.
    Nat Med. 2024 Jun 17. doi: 10.1038/s41591-024-03127.
    PubMed    
    
    
    May 2024
33. SHANKS HRC, Chen K, Reiman EM, Blennow K, et al
    p75 neurotrophin receptor modulation in mild to moderate Alzheimer disease: a randomized, placebo-controlled phase 2a trial.
    Nat Med. 2024 May 17. doi: 10.1038/s41591-024-02977.
    PubMed     Abstract available
    
    
    
34. FORTEA J, Pegueroles J, Alcolea D, Belbin O, et al
    APOE4 homozygozity represents a distinct genetic form of Alzheimer's disease.
    Nat Med. 2024 May 6. doi: 10.1038/s41591-024-02931.
    PubMed     Abstract available
    
    
    
35. XU Q, Liang Z, Huang Y
    APOE4 homozygosity is a new genetic form of Alzheimer's disease.
    Nat Med. 2024 May 6. doi: 10.1038/s41591-024-02923.
    PubMed    
    
    
    March 2024
36. O'LEARY K
    A timeline of biomarker changes before Alzheimer's disease.
    Nat Med. 2024 Mar 15. doi: 10.1038/d41591-024-00018.
    PubMed    
    
    
    February 2024
37. BARTHELEMY NR, Salvado G, Schindler S, He Y, et al
    Highly Accurate Blood Test for Alzheimer's Disease Comparable or Superior to Clinical CSF Tests.
    Nat Med. 2024 Feb 21. doi: 10.1038/s41591-024-02869.
    PubMed     Abstract available
    
    
    January 2024
38. JUCKER M, Walker LC
    Evidence for iatrogenic transmission of Alzheimer's disease.
    Nat Med. 2024 Jan 29. doi: 10.1038/s41591-023-02768.
    PubMed    
    
    
    
39. BANERJEE G, Farmer SF, Hyare H, Jaunmuktane Z, et al
    Iatrogenic Alzheimer's disease in recipients of cadaveric pituitary-derived growth hormone.
    Nat Med. 2024 Jan 29. doi: 10.1038/s41591-023-02729.
    PubMed     Abstract available
    
    
    
40. O'LEARY K
    Modeling real-world data to repurpose drugs for Alzheimer's disease.
    Nat Med. 2024 Jan 18. doi: 10.1038/d41591-024-00003.
    PubMed    
    
    
    December 2023
41. O'LEARY K
    Positive results in Alzheimer's disease trials.
    Nat Med. 2023;29:2973.
    PubMed    
    
    
    November 2023
42. SANCHEZ VELA P, Trowbridge JJ, Levine RL
    Author Correction: Clonal hematopoiesis, aging and Alzheimer's disease.
    Nat Med. 2023 Nov 20. doi: 10.1038/s41591-023-02718.
    PubMed    
    
    
    October 2023
43. MUMMERY CJ, Borjesson-Hanson A, Blackburn DJ, Vijverberg EGB, et al
    Author Correction: Tau-targeting antisense oligonucleotide MAPT(Rx) in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial.
    Nat Med. 2023 Oct 16. doi: 10.1038/s41591-023-02639.
    PubMed    
    
    
    September 2023
44. LONGO FM, Massa SM
    Senolytic therapy for Alzheimer's disease.
    Nat Med. 2023 Sep 27. doi: 10.1038/s41591-023-02541.
    PubMed    
    
    
    
45. GONZALES MM, Garbarino VR, Kautz TF, Palavicini JP, et al
    Senolytic therapy in mild Alzheimer's disease: a phase 1 feasibility trial.
    Nat Med. 2023 Sep 7. doi: 10.1038/s41591-023-02543.
    PubMed     Abstract available
    
    
    
46. SELF WK, Holtzman DM
    Emerging diagnostics and therapeutics for Alzheimer disease.
    Nat Med. 2023 Sep 4. doi: 10.1038/s41591-023-02505.
    PubMed     Abstract available
    
    
    August 2023
47. 
    Events in the brain during the evolution of Alzheimer's disease.
    Nat Med. 2023 Aug 7. doi: 10.1038/s41591-023-02477.
    PubMed    
    
    
    
48. JOHNSON ECB, Bian S, Haque RU, Carter EK, et al
    Cerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer's disease.
    Nat Med. 2023 Aug 7. doi: 10.1038/s41591-023-02476.
    PubMed     Abstract available
    
    
    
49. 
    A fluid biomarker accurately detects tau aggregate pathology in Alzheimer's disease.
    Nat Med. 2023 Aug 2. doi: 10.1038/s41591-023-02468.
    PubMed    
    
    
    
50. PALMQVIST S, Rossi M, Hall S, Quadalti C, et al
    Cognitive effects of Lewy body pathology in clinically unimpaired individuals.
    Nat Med. 2023;29:1971-1978.
    PubMed     Abstract available
    
    
    
51. QUADALTI C, Palmqvist S, Hall S, Rossi M, et al
    Clinical effects of Lewy body pathology in cognitively impaired individuals.
    Nat Med. 2023;29:1964-1970.
    PubMed     Abstract available
    
    
    July 2023
52. O'LEARY K
    Putting the brakes on Alzheimer's disease.
    Nat Med. 2023 Jul 31. doi: 10.1038/d41591-023-00067.
    PubMed    
    
    
    
53. HORIE K, Salvado G, Barthelemy NR, Janelidze S, et al
    CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer's disease.
    Nat Med. 2023 Jul 13. doi: 10.1038/s41591-023-02443.
    PubMed     Abstract available
    
    
    
54. SANCHEZ VELA P, Trowbridge JJ, Levine RL
    Clonal hematopoiesis, aging and Alzheimer's disease.
    Nat Med. 2023 Jul 4. doi: 10.1038/s41591-023-02406.
    PubMed    
    
    
    June 2023
55. BOUZID H, Belk JA, Jan M, Qi Y, et al
    Clonal hematopoiesis is associated with protection from Alzheimer's disease.
    Nat Med. 2023 Jun 15. doi: 10.1038/s41591-023-02397.
    PubMed     Abstract available
    
    
    May 2023
56. BELLAVER B, Povala G, Ferreira PCL, Ferrari-Souza JP, et al
    Astrocyte reactivity influences amyloid-beta effects on tau pathology in preclinical Alzheimer's disease.
    Nat Med. 2023 May 29. doi: 10.1038/s41591-023-02380.
    PubMed     Abstract available
    
    
    
57. LJUBENKOV PA, Rabinovici GD
    Silencing tau to treat early Alzheimer's disease.
    Nat Med. 2023 May 17. doi: 10.1038/s41591-023-02357.
    PubMed    
    
    
    
58. LOPERA F, Marino C, Chandrahas AS, O'Hare M, et al
    Resilience to autosomal dominant Alzheimer's disease in a Reelin-COLBOS heterozygous man.
    Nat Med. 2023 May 15. doi: 10.1038/s41591-023-02318.
    PubMed     Abstract available
    
    
    April 2023
59. MUMMERY CJ, Borjesson-Hanson A, Blackburn DJ, Vijverberg EGB, et al
    Tau-targeting antisense oligonucleotide MAPT(Rx) in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial.
    Nat Med. 2023 Apr 24. doi: 10.1038/s41591-023-02326.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Alzheimer's Disease is free of charge.